Success Metrics

Completion Rate

0%(0/2)

Active Trials

0(0%)

Terminated

2(67%)

Phase Distribution

Ph phase_1

67%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

2(66.7%)

Phase 2Efficacy & side effects

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Terminated(3)

Detailed Status

Terminated2

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (66.7%)

Phase 21 (33.3%)

Trials by Status

terminated267%

withdrawn133%

Recent Activity

0 active trials

Showing 3 of 3

withdrawnphase_1

CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery

NCT00635245

terminatedphase_1

Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

NCT00976508

terminatedphase_2

A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer

NCT00977561

Clinical Trials (3)

Showing 3 of 3 trials

NCT00635245Phase 1

CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery

Withdrawn

NCT00976508Phase 1

Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

Terminated

NCT00977561Phase 2

A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer

Terminated

All 3 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 3